Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 43-9006 versus placebo in unresectable or metastatic renal cell cancer
ACTRN12605000643673Phase 3Completed
- Sponsor
- Bayer
- Start
- Nov 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Sorafenib + best supportive care with Placebo + best supportive care (2 arms). Primary endpoint: Overall survival. Started Nov 2003; status: completed.
02
Drugs
sorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ACTRN12605000643673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000643673.